Emmanuèle Lechapt-Zalcman, Guénaëlle Levallet, Audrey Emmanuelle Dugué, Anne Vital, Marie-Danièle Diebold, Philippe Menei, Philippe Colin, Philippe Peruzzy, Evelyne Emery, Myriam Bernaudin, Françoise Chapon and Jean-Sébastien Guillamo O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide Cancer 118
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27441
O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and low MGMT expression are predictors of improved prognosis in patients with newly diagnosed glioblastoma who undergo surgical resection and receive carmustine-releasing wafer implants followed by a protocol of adjuvant radiotherapy and concomitant oral temozolomide chemotherapy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field